Blood saving possibilities in delivering patients with placenta increta
https://doi.org/10.35401/2500-0268-2019-14-2-67-75
Abstract
According to the results of systematic reviews of WHO, maternal mortality associated with massive bleeding almost reached 30% and has no tendency to decrease. Among the causes of massive obstetric hemorrhage, the most challenging ones are uterine hypotension and morbidity adherence placenta. Most severe complication for placentation is placenta increta in the uterine wall. Over the past 50 years, the number of cases with morbidity adherence placenta has increased tenfold. By all indications, this pathology has taken on the character of an epidemic and is one of the main causes for massive blood loss and blood transfusion, as well as peripartum hysterectomy. For surgical hemostasis in this pathology we apply X-ray vascular methods (temporary balloon occlusion of large vessels, vascular embolization), ligation of the iliac, uterine, ovarian arteries, various versions of distal hemostasis, including the use of uterine turnstiles, intrauterine and vaginal cylinders, compression sutures. However, data confirming the advantage of any specified methods are not enough. The risk of massive bleeding is high while using any of these methods. The article analyzes the blood saving methods existing at the present stage and possibility of these methods usage in obstetrics. Besides, we describe efficacy and safety of their use in massive blood loss, including the surgical treatment of morbidity adherence placenta.
About the Authors
E. N. Plakhotina
Vidnovsky Perinatal Center, Moscow region
Russian Federation
Russian Federation
Plakhotina Elena N. – Dr. of Sci. (Med.), Head of Anesthesiology and Resuscitation, Vidnovsky Perinatal Center
142700, Moscow region, Vidnoe, 17, Zavodskaya str.
T. N. Belousova
Vidnovsky Perinatal Center, Moscow region
Russian Federation
Russian Federation
Belousova Tamara N. – Cand. of Sci. (Med), Сhief doctor of Vidnovsky Perinatal Center
142700, Moscow region, Vidnoe, 17, Zavodskaya str.
I. A. Kulikov
Vidnovsky Perinatal Center, Moscow region
Russian Federation
Russian Federation
Kulikov Ilyas A. – Cand. of Sci. (Med), Head of the department of pathology of pregnancy, Vidnovsky Perinatal Center
142700, Moscow region, Vidnoe, 17, Zavodskaya str.
K. M. Pavlyutina
Vidnovsky Perinatal Center, Moscow region
Russian Federation
Russian Federation
Pavlyutina Karina M. – anesthesiologist-resuscitator of the Department of Anesthesiology and Resuscitation
142700, Moscow region, Vidnoe, 17, Zavodskaya str.
R. V. Latyshev
Vidnovsky Perinatal Center, Moscow region
Russian Federation
Russian Federation
Latyshev Roman V. – anesthesiologist-resuscitator of the Department of Anesthesiology and Resuscitation
142700, Moscow region, Vidnoe, 17, Zavodskaya str.
References
1. Global causes of maternal death: a WHO systematic analysis/ Lale Say, Doris Chou, Alison Gemmill et al.// Lancet Glob Health. 2014. Т.2, №6. P. 323-333. DOI: 10.1016/S2214-109X(14)70227-X
2. Clinical Analysis of Postpartum Hemorrhage Requiring Massive Transfusions at a Tertiary Center./ Hu J, Yu ZP, Wang P et al.// Chin Med Journal. 2017. №130. P. 581-585. DOI: 10.4103/0366-6999.200545
3. Kerry L. How do we manage blood product support in the massively hemorrhaging obstetric patient?/ L.Kerry, O’Brien, Lynne Uhl//Transfusion. 2016;56(9):2165-71. DOI: 10.1111/trf.13753
4. Center of excellence for placenta accrete/ R.M. Silver, K.A. Fox, J.R. Barton et al.//American Journal of Obstetrics & Gynecology. 2015.-May; 212(5):561-568. DOI:10.1016/j.ajog.2014.11.018
5. A Standardized Approach for Transfusion Medicine Support in Patients With Morbidly Adherent Placenta/ A.K. Panigrahi, A. Yeaton-Massey, S. Bakhtary et al.// Anesthesia and analgesia. 2017;125(2):603-608. DOI: 10.1213/ANE.0000000000002050
6. Silver R.M. Placenta accreta spectrum: accreta, increta, and percreta. / R.M. Silver, K.D. Barbour //Obstet Gynecol Clin North Am. 2015 Jun;42(2):381-402. DOI: 10.1016/j.ogc.2015.01.014.
7. Within country inequalities in caesarean section rates: observational study of 72 low and middle income countries/ A.A. Boatin, A. Schlotheuber, A. P. Betran, // BMJ. 2018;360:55 DOI: https://doi.org/10.1136/bmj.k55
8. Robson S. J. Thirty years of the World Health Organization’s target caesarean section rate: time to move on/ SJ Robson, C. M. de Costa //Med J Aust. 2017 Mar 6;206(4):181-185. DOI:10.5694/mja16.00832
9. Maternal morbidity associated with multiple repeat cesarean deliveries: National Institute of Child Health and Human Development maternal-fetal medicine units network/ R.M. Silver, M.B. Landon, D.J. Rouse at al. // Obstetrics & Gynecology.- 2006;107:1226-32. DOI:10.1097/01.aog.0000219750.79480.84
10. Obstetric Intensive Care Manual/ M.R. Foley et al. - 3 edition. -Postpartum hemorrhage, 2010.-29 с.
11. Screening for morbidly adherent placenta in early pregnancy/ J. Panaiotova, M. Tokunaka, K. Krajewska et al// Ultrasound in obstetrics & gynecology. 2019;53:101-106 DOI: 10.1002/uog.20104
12. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study/ K. Fitzpatrick, S. Sellers, P. Spark et al. // BJOG. 2013 Aug 7. DOI: 10.1111/1471-0528.12405
13. Efrain Riveros-Perez. Retrospective analysis of obstetric and anesthetic management of patients with placenta accreta spectrum disorders./ Riveros-Perez E, Wood C.// International Journal of Gynecology & Obstetrics. 2018 Mar;140(3):370-374. DOI: 10.1002/ijgo.12366
14. Management of placenta accreta, diagnosed before birth./A.Dimitrov, T. Garnizov, B. Frundeva et al. // Akush Ginekol (Sofiia). 2015;54(8):13-21.
15. Alternative approaches to surgical hemostasis in patients with morbidly adherent placenta undergoing fertility-sparing surgery./ R.G. Shmakov, A.A. Vinitskiy, V.D. Chuprinin, et al.// Journal Matern Fetal Neonatal Med. 2018 Feb 5:1-7. DOI:10.1080/14767058.2018.1424821
16. Perioperative and transfusion outcomes in women undergoing cesarean hysterectomy for abnormal placentation / K.F. Brookfield, L.T. Goodnough, D.J. Lyell et al// Transfusion. 2014 Jun; 54(6): 1530-1536. DOI: 10.1111/trf.12483
17. The effects of sevoflurane on isolated gravid human myometrium. / R.J. Turner, M. Lambrost, C. Holmes et al // Anaesth Intensive Care. 2002;30:591-6. DOI: 10.1177/0310057X0203000508
18. Afolabi BB. Regional versus general anaesthesia for caesarean section. / B.B. Afolabi, F.E. Lesi // Cochrane Database Syst Rev. 2006;(10):CD004350. DOI: 10.1002/14651858.CD004350.pub3.
19. The contribution of anaesthesia modus on reducing blood loss during caesarean section./V. Liberis, P. Tsikouras ,T. Vogiatzaki et al. // Clin Exp Obstet Gynecol. 2009;36: 105-109.
20. Riveros-Perez E. Obstetrics Retrospective analysis of obstetric and anesthetic management of patients with placenta accreta spectrum disorders/ E. Riveros-Perez E, C. Wood // Int J Gynaecol Obstet. 2018 Mar;140(3):370-374. DOI: 10.1002/ijgo.12366
21. Mode of anesthesia and clinical outcomes of patients undergoing Cesarean delivery for invasive placentation: A retrospective cohort study of 50 consecutive cases./ N. Nguyen-Lu, J.C. Carvalho, J. Kingdom et al. //Can J Anaesth. 2016;63:1233-1244. DOI: 10.1007/s12630-016-0695-x.
22. Comparison of general and epidural anesthesia in elective cesarean section for placenta previa totalis: Maternal hemodynamics, blood loss and neonatal outcome. / J.Y. Hong, Y.S. Jee, H.J. Yoon et al.// Int J Obstet Anesth. 2003;12:12-16. DOI:10.1016/s0959-289x(02)00183-8
23. FIGO consensus guidelines on placenta accreta spectrum disorders: Nonconservative surgical management/ L. Allen, E. Jauniaux, S. Hobson et al. // International Journal of Gynecology&Obstetrics. 2018;140(3):281-290. DOI: 10.1002/ijgo.12409
24. Toledano R.D. Anesthetic and Obstetric Management of Placenta Accreta: Clinical Experience and Available Evidence/R.D. Toledano, L. R. Leffert et al. // Current Anesthesiology Reports. 2017;7(1):93-102.
25. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology First update 2016/ S.A. Kozek-Langenecker, A.B. Ahmed, A. Afshari et al// European Journal of Anaesthesiology. 2017;34:332-395. DOI: 10.1097/EJA.0000000000000630.
26. Perioperative and transfusion outcomes in women undergoing cesarean hysterectomy for abnormal placentation/K. F. Brookfield, L.T. Goodnough, D. J. Lyell et al//Transfusion. 2014 Jun; 54(6): 1530–1536. DOI: 10.1111/trf.12483
27. Clinical Management Guidelines for Obstetrician– Gynecologists. Postpartum Hemorrhage/Practice bullet// American College of Obstetricians and Gynecologists (ACOG). 2017;183:168-178.
28. Jiburt Е.В. «Novie» gemotransmissivnie infekcii i ih profilaktika/ E.B. Jiburt // Vestnik «MEDSI». 2012;16:33-39.
29. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry/L.E. Phillips, C. McLintock, W. Pollock et al. // Anesth Analg. 2009 Dec;109(6):1908-15. DOI: 10.1213/ANE.0b013e3181c039e6.
30. Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology./M. Murakami ,T. Kobayashi , T. Kubo et al.// J Obstet Gynaecol Res 2015 Aug;41(8):1161-8. DOI: 10.1111/jog.12712
31. Recombinant activated factor VII (rFVIIa/ NovoSeven®) in the management of severe postpartum haemorrhage: initial report of a multicentre case series in Japan./ T.Kobayashi, M. Nakabayashi , A. Yoshioka et al.// Int J Hematol. 2012 Jan;95(1):57-63. DOI: 10.1007/s12185-011-0974-9.
32. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. /A.J. Wikkelsø, H.M. Edwards, A. Afshari et al. // Br J Anaesth.- 2015 Apr;114(4):623-33. DOI: 10.1093/bja/aeu444.
33. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage-an observational study./S. Ahmed , C. Harrity , S. Johnson et al//Transfus Med. 2012 Oct;22(5):344-9. DOI: 10.1111/j.1365-3148.2012.01178.x.
34. Physiological changes in pregnancy. /P. Soma-Pillay, C. Nelson-Piercy, H. Tolppanen et al. // Cardiovascular Journal of Africa. 2016;27(2):89-94. DOI:10.5830/cvja-2016-021
35. Coagulation factors in whole blood collected from pregnant women and stored at 4°C/ M. Minatoguchi, A. Itakura, A. Miki et al.// Nagoya J Med Sci. 2016 Feb; 78(1): 1-7.
36. Safety and efficacy of preoperative autologous blood donation for high-risk pregnant women: experience of a large university hospital in Japan./ Y. Yamamoto , T. Yamashita , N.H. Tsuno et al// J Obstet Gynaecol Res. 2014 May;40(5):1308-16. DOI: 10.1111/jog.12348.
37. Krovesberegayuschie tehnologii v akusherskoi praktike: klinicheskie rek-omendacii/ G.T. Suhih, V.N. Serov, L.V. Adamyan// Klinicheskie rek-omendacii utv. Rossiiskim obschestvom akusherov_ginekologov. 2014; 15-21.
38. Walunj Ajit. Autologous blood transfusion./ A. Walunj, A. Babb , R. Sharpe// Continuing Education in Anaesthesia Critical Care & Pain.- 2006; Volume 6, Issue 5, Pages 192-196. DOI:10.1093/bjaceaccp/mkl042
39. Prevention and Management of Postpartum Haemorrhage. / Royal College of Obstetricians & Gynaecologists.// Guideline № 52. Desember 2016
40. Jadon A. Blood transfusion practices in obstetric anaesthesia./A. Jadon, R. Bagai. // Indian Jounal Anaesth. 2014;58(5):629-636. DOI: 10.4103/0019-5049.144674
41. The development and implementation of an obstetric cell salvage service./ N.J. McDonnell, D. Kennedy, L.J. Long et al.// Anaesth Intensive Care. 2010;38:492-499. DOI: 10.1177/0310057X1003800313
42. Elagamy A. The use of cell salvage in women undergoing cesarean hysterectomy for abnormal placentation. / A. Elagamy, A. Abdelaziz ,M. Ellaithy// Int J Obstet Anesth. 2013;22:289-293. DOI: 10.1016/j.ijoa.2013.05.007
43. Lew E. Implementation of an obstetric cell salvage service in a tertiary women’s hospital./ E. Lew, S. Tagore // Singapore Med J. 2015;56:445-449. DOI: 10.11622/smedj.2015121
44. Cell salvage and donor blood transfusion during cesarean section: A pragmatic, multicentre randomised controlled trial (SALVO) / K.S. Khan, Moore PAS, M.J. Wilson et al//PLoS Med. 2017;14(12) DOI:10.1371/journal.pmed.1002471
45. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): An international, randomised, double-blind, placebo-controlled trial./ H. Shakur, I. Roberts ,B. Fawole et al. // Lancet. 2017;389:2105-2116. DOI: 10.1016/S0140-6736(17)30638-4
46. Tranexamic acid for preventing postpartum blood loss after cesarean delivery: A systematic review and meta-analysis of randomized controlled trials. / G. Simonazzi, M. Bisulli , G. Saccone et al.// Acta Obstet Gynecol Scand. 2016;95:28-37. DOI: 10.1111/aogs.12798
47. Lakshmi S.D. Role of prophylactic tranexamic acid in reducing blood loss during elective caesarean section: A randomized controlled study. / S.D. Lakshmi, R.J. Abraham // Clin Diagn Res. 2016;10:17-21. DOI: 10.7860/JCDR/2016/21702.9050
48. Role of Intravenous tranexamic acid on caesarean blood loss:A prospective randomised study./ I. Ray, R. Bhattacharya ,S. Chakraborty et al. // J Obstet Gynaecol India. 2017;66:347-352. DOI: 10.1007/s13224-016-0915-x.
49. A randomized placebo-controlled trial of preoperative tranexamic acid among women undergoing elective cesarean delivery. / A.M. Maged, O.M. Helal, M.M. Elsherbin et al. // Int J Gynecol Obstet. 2015;131:265-268. DOI: 10.1016/j.ijgo.2015.05.027
Review
For citations:
Plakhotina E.N., Belousova T.N., Kulikov I.A., Pavlyutina K.M., Latyshev R.V. Blood saving possibilities in delivering patients with placenta increta. Innovative Medicine of Kuban. 2019;(2):67-75. (In Russ.) https://doi.org/10.35401/2500-0268-2019-14-2-67-75
Views:
1686
Email this article 
